{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:10:06Z","timestamp":1790809806240,"version":"4.1.0"},"publisher-location":"Singapore","reference-count":94,"publisher":"Springer Singapore","isbn-type":[{"value":"9789813360433","type":"print"},{"value":"9789813360440","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-33-6044-0_26","type":"book-chapter","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T21:08:40Z","timestamp":1617916120000},"page":"515-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychedelic Medicines in Major Depression: Progress and Future Challenges"],"prefix":"10.1007","author":[{"given":"Jose Carlos","family":"Bouso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen\u00eds","family":"Ona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael G.","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"26_CR1","volume-title":"Stimulants. Handbook of psychopharmacology","author":"LE Hollister","year":"1978","unstructured":"Hollister LE (1978) Psychotomimetic drugs in man. In: Iversen LL, Iversen SD, Snyder SH (eds) Stimulants. Handbook of psychopharmacology, vol 11. Springer, Boston"},{"key":"26_CR2","first-page":"73","volume":"2","author":"CD Nichols","year":"2001","unstructured":"Nichols CD, Sanders-Bush E (2001) Serotonin receptor signaling and hallucinogenic drug action. Heffter Rev Psych Res 2:73\u201379","journal-title":"Heffter Rev Psych Res"},{"key":"26_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","volume":"65","author":"BP Akers","year":"2011","unstructured":"Akers BP, Ruiz JF, Piper A, Ruck CAP (2011) A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Econ Bot 65:121\u2013128","journal-title":"Econ Bot"},{"key":"26_CR4","volume-title":"The road to Eleusis: unveiling the secret of the mysteries","author":"RG Wasson","year":"2008","unstructured":"Wasson RG, Hofmann A, Ruck CAP (2008) The road to Eleusis: unveiling the secret of the mysteries. North Atlantic Books, Berkeley"},{"key":"26_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","volume":"142","author":"JJ Rucker","year":"2018","unstructured":"Rucker JJ, Iliff J, Nutt DJ (2018) Psychiatry and the psychedelic drugs. Past, present & future. Neuropharmacology 142:200\u2013218","journal-title":"Neuropharmacology"},{"key":"26_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","volume":"235","author":"KR Bonson","year":"2018","unstructured":"Bonson KR (2018) Regulation of human research with LSD in the United States (1949\u20131987). Psychopharmacology (Berlin) 235:591\u2013604","journal-title":"Psychopharmacology (Berlin)"},{"key":"26_CR7","doi-asserted-by":"publisher","unstructured":"Ona G, Bouso JC (2019) Can psychedelics be the treatment for the crisis in psychopharmacology? Preprints. https:\/\/doi.org\/10.20944\/preprints201901.0249.v1","DOI":"10.20944\/preprints201901.0249.v1"},{"key":"26_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2017.09.012","volume":"81","author":"S Reiche","year":"2018","unstructured":"Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majic T (2018) Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: a systematic review. Prog Neuro-Psychopharmacol Biol Psychiatry 81:1\u201310","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"26_CR9","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"26_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71\u201378","journal-title":"Arch Gen Psychiatry"},{"key":"26_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202:513\u2013520","journal-title":"J Nerv Ment Dis"},{"key":"26_CR12","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165\u20131180","journal-title":"J Psychopharmacol"},{"key":"26_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49:655\u2013663","journal-title":"Psychol Med"},{"key":"26_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"L Os\u00f3rio Fde","year":"2015","unstructured":"Os\u00f3rio Fde L, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37:13\u201320","journal-title":"Rev Bras Psiquiatr"},{"key":"26_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima Os\u00f3rio F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L et al (2016) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36:77\u201381","journal-title":"J Clin Psychopharmacol"},{"key":"26_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"26_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE et al (2018) Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235:399\u2013408","journal-title":"Psychopharmacology"},{"key":"26_CR18","unstructured":"Griffiths R, Barrett F, Darrick M, Johnson M, Mary C, Patrick F, Alan D (2019) Psilocybin-assisted treatment of major depressive disorder: results from a randomized trial. Poster presented at the 58th annual meeting of the American College of Neuropsychopharmacology. Orlando, Florida, 8\u201311 December"},{"key":"26_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fpsyg.2019.01234","volume":"10","author":"RN de Almeida","year":"2019","unstructured":"de Almeida RN, Galv\u00e3o ACM, da Silva FS, Silva EADS, Palhano-Fontes F, Maia-de-Oliveira JP et al (2019) Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol 10:1234","journal-title":"Front Psychol"},{"key":"26_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fpsyt.2018.00185","volume":"9","author":"ACM Galv\u00e3o","year":"2018","unstructured":"Galv\u00e3o ACM, Almeida RN, Silva EAS, Freire FA, Palhano-Fontes F, Onias H et al (2018) Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychol 9:185","journal-title":"Front Psychol"},{"issue":"1","key":"26_CR21","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","volume":"7","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 7(1):13187","journal-title":"Sci Rep"},{"key":"26_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","volume":"35","author":"JB Stroud","year":"2018","unstructured":"Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL (2018) Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology 35:459\u2013466","journal-title":"Psychopharmacology"},{"key":"26_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","volume":"138","author":"D Erritzoe","year":"2018","unstructured":"Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ et al (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 138:368\u2013378","journal-title":"Acta Psychiatr Scand"},{"key":"26_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3389\/fpsyg.2018.01721","volume":"9","author":"T Lyons","year":"2018","unstructured":"Lyons T, Carhart-Harris RL (2018) More realistic forecasting of future life events after psilocybin for treatment-resistant depression. Front Psychol 9:1721","journal-title":"Front Psychol"},{"key":"26_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12888-019-2288-z","volume":"19","author":"RG Dos Santos","year":"2019","unstructured":"Dos Santos RG, Bouso JC, Hallak JEC (2019) Serotonergic hallucinogens\/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC Psychiatry 19:321","journal-title":"BMC Psychiatry"},{"key":"26_CR26","unstructured":"COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression. PRNewswire, October 23, 2018. Accessed on December 18 at: https:\/\/www.prnewswire.com\/news-releases\/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html"},{"key":"26_CR27","unstructured":"Psilocybin for major depression granted Breakthrough Therapy by FDA. New Atlas, November 24, 2019. Accessed on December 18 at: https:\/\/newatlas.com\/science\/psilocybin-major-depression-mdd-usona-breakthrough-therapy-fda\/"},{"key":"26_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","volume":"3","author":"FX Vollenweider","year":"2001","unstructured":"Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci 3:265\u2013279","journal-title":"Dialogues Clin Neurosci"},{"key":"26_CR29","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","volume":"38","author":"EJ Kyzar","year":"2017","unstructured":"Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV (2017) Psychedelic drugs in biomedicine. Trends Pharmacol Sci 38:992","journal-title":"Trends Pharmacol Sci"},{"key":"26_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357\u2013372","journal-title":"Neuropsychopharmacology"},{"key":"26_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","volume":"27","author":"KH Preller","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, St\u00e4mpfli P et al (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27:451\u2013457","journal-title":"Curr Biol"},{"key":"26_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neubiorev.2016.10.026","volume":"71","author":"RG dos Santos","year":"2016","unstructured":"dos Santos RG, Os\u00f3rio FL, Crippa JAS, Hallak JEC (2016) Classical hallucinogens and neuroimaging: a systematic review of human studies. Neurosci Biobehav Rev 71:715\u2013728","journal-title":"Neurosci Biobehav Rev"},{"key":"26_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1523\/JNEUROSCI.2830-16.2016","volume":"37","author":"V Beliveau","year":"2017","unstructured":"Beliveau V, Ganz M, Feng L, Ozenne B, H\u00f8jgaard L, Fisher PM, Svarer C, Greve DN, Knudsen GM (2017) A high-resolution in vivo atlas of the human brain\u2019s serotonin system. J Neurosci 37:120\u2013128","journal-title":"J Neurosci"},{"key":"26_CR34","doi-asserted-by":"publisher","unstructured":"Ona G, Bouso JC (2019) Therapeutic potential of natural psychoactive drugs for central nervous system disorders: a perspective from polypharmacology. Curr Med Chem 26. https:\/\/doi.org\/10.2174\/0929867326666191212103330","DOI":"10.2174\/0929867326666191212103330"},{"key":"26_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","volume":"242","author":"D De Gregorio","year":"2018","unstructured":"De Gregorio D, Enns JP, Nu\u00f1ez NA, Posa L, Gobbi G (2018) D-lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res 242:69\u201396","journal-title":"Prog Brain Res"},{"issue":"Pt A","key":"26_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","volume":"113","author":"D De Gregorio","year":"2016","unstructured":"De Gregorio D, Posa L, Ochoa-S\u00e1nchez R, McLaughlin R, Maione S, Comai S, Gobbi G (2016) The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res 113(Pt A):81\u201391","journal-title":"Pharmacol Res"},{"key":"26_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/138161207779313740","volume":"13","author":"TL Collier","year":"2007","unstructured":"Collier TL, Waterhouse RN, Kassiou M (2007) Imaging sigma receptors: applications in drug development. Curr Pharm Des 13:51\u201372","journal-title":"Curr Pharm Des"},{"key":"26_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0014-2999(96)00497-9","volume":"312","author":"K Matsuno","year":"1996","unstructured":"Matsuno K, Kobayashi T, Tanaka MK, Mita S (1996) Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 312:267\u2013271","journal-title":"Eur J Pharmacol"},{"key":"26_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1124\/jpet.107.124685","volume":"322","author":"D Wang","year":"2007","unstructured":"Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K et al (2007) Role of N-methyl-D-aspartate receptors in antidepressant-like effects of sigma 1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats. J Pharmacol Exp Ther 322:1305\u20131314","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fphar.2019.00528","volume":"10","author":"K Yang","year":"2019","unstructured":"Yang K, Wang C, Sun T (2019) The roles of intracellular chaperone proteins, sigma receptors, in Parkinson\u2019s disease (PD) and major depressive disorder (MDD). Front Pharmacol 10:528","journal-title":"Front Pharmacol"},{"key":"26_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/0973-7847.120524","volume":"7","author":"M Moloudizargari","year":"2013","unstructured":"Moloudizargari M, Mikaili P, Aghajanshakeri S, Asghari MH, Shayegh J (2013) Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev 7:199\u2013212","journal-title":"Pharmacogn Rev"},{"key":"26_CR42","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, S\u00e1nchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228:481\u2013491","journal-title":"Exp Brain Res"},{"key":"26_CR43","doi-asserted-by":"publisher","first-page":"19575","DOI":"10.1073\/pnas.0905884106","volume":"106","author":"KA Jones","year":"2009","unstructured":"Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A 106:19575\u201319580","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/7854_2017_480","volume":"36","author":"GJ Marek","year":"2018","unstructured":"Marek GJ (2018) Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons. Curr Top Behav Neurosci 36:107\u2013135","journal-title":"Curr Top Behav Neurosci"},{"key":"26_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.pbr.2018.08.003","volume":"242","author":"KS Murnane","year":"2018","unstructured":"Murnane KS (2018) The renaissance in psychedelic research: what do preclinical models have to offer. Prog Brain Res 242:25\u201367","journal-title":"Prog Brain Res"},{"key":"26_CR46","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23:3170\u20133182","journal-title":"Cell Rep"},{"key":"26_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1055\/s-2007-1004594","volume":"41","author":"R Hellweg","year":"2008","unstructured":"Hellweg R, Ziegenhorn A, Heuser I, Deuschle M (2008) Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 41:66\u201371","journal-title":"Pharmacopsychiatry"},{"key":"26_CR48","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/mp.2010.98","volume":"16","author":"ML Molendijk","year":"2011","unstructured":"Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Elzinga BM (2011) Serum levels of brain-derived neurotrophic factor in major depressive disorder: state\u2013trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16:1088\u20131095","journal-title":"Mol Psychiatry"},{"key":"26_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22:238\u2013249","journal-title":"Nat Med"},{"key":"26_CR50","doi-asserted-by":"publisher","first-page":"8056370","DOI":"10.1155\/2016\/8056370","volume":"2016","author":"H Qiao","year":"2016","unstructured":"Qiao H, Li MX, Xu C, Chen HB, An SC, Ma XM (2016) Dendritic spines in depression: what we learned from animal models. Neural Plast 2016:8056370","journal-title":"Neural Plast"},{"key":"26_CR51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/mp.2017.61","volume":"22","author":"E Castr\u00e9n","year":"2017","unstructured":"Castr\u00e9n E, Antila H (2017) Neuronal plasticity and neurotrophic factors in drug responses. Mol Psychiatry 22:1085\u20131095","journal-title":"Mol Psychiatry"},{"key":"26_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fnhum.2014.00377","volume":"8","author":"B Kolb","year":"2014","unstructured":"Kolb B, Muhammad A (2014) Harnessing the power of neuroplasticity for intervention. Front Hum Neurosci 8:377","journal-title":"Front Hum Neurosci"},{"key":"26_CR53","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.drudis.2009.05.002","volume":"14","author":"JH Krystal","year":"2009","unstructured":"Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE et al (2009) Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today 14:690\u2013697","journal-title":"Drug Discov Today"},{"key":"26_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","volume":"73","author":"R Strassman","year":"1996","unstructured":"Strassman R (1996) Human psychopharmacology of N, N-dimethyltryptamine. Behav Brain Res 73:121\u2013124","journal-title":"Behav Brain Res"},{"key":"26_CR55","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 109:2138\u20132143","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26_CR56","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1002\/hbm.22562","volume":"35","author":"E Tagliazucchi","year":"2014","unstructured":"Tagliazucchi E, Carhart-Harris RL, Leech R, Nutt D, Chialvo DR (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 35:5442\u20135456","journal-title":"Hum Brain Mapp"},{"key":"26_CR57","doi-asserted-by":"publisher","first-page":"e0118143","DOI":"10.1371\/journal.pone.0118143","volume":"10","author":"F Palhano-Fontes","year":"2015","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JA, Hallak JE et al (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One 10:e0118143","journal-title":"PLoS One"},{"key":"26_CR58","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H et al (2016) Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 26:1043\u20131050","journal-title":"Curr Biol"},{"key":"26_CR59","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","volume":"18","author":"F M\u00fcller","year":"2018","unstructured":"M\u00fcller F, Dolder PC, Schmidt A, Liechti ME, Borgwardt S (2018) Altered network hub connectivity after acute LSD administration. Neuroimage Clin 18:694\u2013701","journal-title":"Neuroimage Clin"},{"key":"26_CR60","first-page":"49","volume":"89","author":"A Mohan","year":"2016","unstructured":"Mohan A, Roberto AJ, Mohan A, Lorenzo A, Jones K, Carney MJ, Lioger-Wayback L, Hwang S, Lapidus KAB (2016) The significance of the default mode network (DMN) in neurological and neuropsychiatric disorders: a review. Yale J Biol Med 89:49\u201357","journal-title":"Yale J Biol Med"},{"key":"26_CR61","doi-asserted-by":"publisher","first-page":"204512531984577","DOI":"10.1177\/2045125319845774","volume":"9","author":"JM Rocha","year":"2019","unstructured":"Rocha JM, Os\u00f3rio FL, Crippa JAS, Bouso JC, Rossi GN, Hallak JEC, dos Santos RG (2019) Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Ther Adv Psychopharmacol 9:204512531984577","journal-title":"Ther Adv Psychopharmacol"},{"key":"26_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.31887\/DCNS.2015.17.4\/apringle","volume":"17","author":"A Pringle","year":"2015","unstructured":"Pringle A, Harmer CJ (2015) The effects of drugs on human models of emotional processing: an account of antidepressant drug treatment. Dialogues Clin Neurosci 17:477\u2013487","journal-title":"Dialogues Clin Neurosci"},{"key":"26_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.euroneuro.2015.01.008","volume":"25","author":"JC Bouso","year":"2015","unstructured":"Bouso JC, Palhano-Fontes F, Rodr\u00edguez-Fornells A, Ribeiro S, Sanches R, Crippa JA et al (2015) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol 25:483\u2013492","journal-title":"Eur Neuropsychopharmacol"},{"key":"26_CR64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1364-6613(00)01483-2","volume":"4","author":"G Bush","year":"2000","unstructured":"Bush G, Luu P, Posner MI (2000) Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4:215\u2013222","journal-title":"Trends Cogn Sci"},{"key":"26_CR65","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/386824a0","volume":"386","author":"WC Drevets","year":"1997","unstructured":"Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386:824\u2013827","journal-title":"Nature"},{"key":"26_CR66","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","volume":"65","author":"AH Miller","year":"2009","unstructured":"Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732\u2013741","journal-title":"Biol Psychiatry"},{"key":"26_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-0-585-37970-8_2","volume":"461","author":"M Maes","year":"1999","unstructured":"Maes M (1999) Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461:25\u201346","journal-title":"Adv Exp Med Biol"},{"key":"26_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","volume":"26","author":"L Capuron","year":"2002","unstructured":"Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH (2002) Neurobehavioral effects of interferon-\u03b1 in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26:643\u2013652","journal-title":"Neuropsychopharmacology"},{"key":"26_CR69","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","volume":"66","author":"NA Harrison","year":"2009","unstructured":"Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD (2009) Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 66:407\u2013414","journal-title":"Biol Psychiatry"},{"key":"26_CR70","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","volume":"237","author":"N Family","year":"2019","unstructured":"Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (2019) Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology 237:841. https:\/\/doi.org\/10.1007\/s00213-019-05417-7","journal-title":"Psychopharmacology"},{"key":"26_CR71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/jpet.108.143461","volume":"327","author":"B Yu","year":"2008","unstructured":"Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (2008) Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327:316\u2013323","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR72","doi-asserted-by":"publisher","first-page":"e75426","DOI":"10.1371\/journal.pone.0075426","volume":"8","author":"F Nau","year":"2013","unstructured":"Nau F, Yu B, Martin D, Nichols CD (2013) Serotonin 5-HT2A receptor activation blocks TNF-\u03b1 mediated inflammation in vivo. PLoS One 8:e75426","journal-title":"PLoS One"},{"key":"26_CR73","doi-asserted-by":"publisher","first-page":"12863","DOI":"10.1038\/s41598-017-12779-5","volume":"7","author":"V Dakic","year":"2017","unstructured":"Dakic V, Minardi J, Costa R, de Moraes R, de Araujo DB, Ribeiro S, Martins-de-Souza D, Rehen SK (2017) Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci Rep 7:12863","journal-title":"Sci Rep"},{"key":"26_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2016.1260189","volume":"49","author":"RG Dos Santos","year":"2017","unstructured":"Dos Santos RG, Hallak JEC (2017) Effects of the natural \u03b2-carboline alkaloid harmine, a main constituent of ayahuasca, in memory and in the hippocampus: a systematic literature review of preclinical studies. J Psychoactive Drugs 49:1\u201310","journal-title":"J Psychoactive Drugs"},{"key":"26_CR75","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/s41598-017-05407-9","volume":"7","author":"JA Morales-Garc\u00eda","year":"2017","unstructured":"Morales-Garc\u00eda JA, de la Fuente Revenga M, Alonso-Gil S, Rodr\u00edguez-Franco MI, Feilding A, Perez-Castillo A, Riba J (2017) The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 7:5309","journal-title":"Sci Rep"},{"key":"26_CR76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2012.01.030","volume":"682","author":"A Pal","year":"2012","unstructured":"Pal A, Fontanilla D, Gopalakrishnan A, Chae YK, Markley JL, Ruoho AE (2012) The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol 682:12\u201320","journal-title":"Eur J Pharmacol"},{"key":"26_CR77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.103.049882","volume":"306","author":"J Riba","year":"2003","unstructured":"Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ (2003) Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306:73\u201383","journal-title":"J Pharmacol Exp Ther"},{"key":"26_CR78","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.pnpbp.2009.07.021","volume":"33","author":"JJ Fortunato","year":"2009","unstructured":"Fortunato JJ, R\u00e9us GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F et al (2009) Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 33:1425\u20131430","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"26_CR79","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4161\/oxim.3.5.13109","volume":"3","author":"GZ R\u00e9us","year":"2010","unstructured":"R\u00e9us GZ, Stringari RB, de Souza B, Petronilho F, Dal-Pizzol F, Hallak JE et al (2010) Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxidative Med Cell Longev 3:325\u2013331","journal-title":"Oxidative Med Cell Longev"},{"key":"26_CR80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fphar.2018.00177","volume":"9","author":"EAD Schindler","year":"2018","unstructured":"Schindler EAD, Wallace RM, Sloshower JA, D\u2019Souza DC (2018) Neuroendocrine associations underlying the persistent therapeutic effects of classic serotonergic psychedelics. Front Pharmacol 9:177","journal-title":"Front Pharmacol"},{"key":"26_CR81","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX et al (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78:544\u2013553","journal-title":"Biol Psychiatry"},{"key":"26_CR82","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1523\/JNEUROSCI.21-10-03572.2001","volume":"21","author":"LD Van de Kar","year":"2001","unstructured":"Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS (2001) 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21:3572\u20133579","journal-title":"J Neurosci"},{"key":"26_CR83","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881108095705","volume":"23","author":"M Di Simplicio","year":"2009","unstructured":"Di Simplicio M, Massey-Chase R, Cowen PJ, Harmer CJ (2009) Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol 23:241\u2013248","journal-title":"J Psychopharmacol"},{"key":"26_CR84","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.psyneuen.2009.05.006","volume":"34","author":"B Costa","year":"2009","unstructured":"Costa B, Pini S, Gabelloni P, Abelli M, Lari L, Cardini A et al (2009) Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology 34:1506\u20131514","journal-title":"Psychoneuroendocrinology"},{"key":"26_CR85","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1016\/j.psyneuen.2013.05.014","volume":"38","author":"K MacDonald","year":"2013","unstructured":"MacDonald K, Macdonald TM, Br\u00fcne M, Lamb K, Wilson MP, Golshan S, Feifel D (2013) Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology 38:2831\u20132843","journal-title":"Psychoneuroendocrinology"},{"key":"26_CR86","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.psyneuen.2012.12.017","volume":"38","author":"SA Vreeburg","year":"2013","unstructured":"Vreeburg SA, Hoogendijk WJ, DeRijk RH, van Dyck R, Smit JH, Zitman FG, Penninx BW (2013) Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. Psychoneuroendocrinology 38:1494\u20131502","journal-title":"Psychoneuroendocrinology"},{"key":"26_CR87","first-page":"375","volume":"36","author":"M Castro","year":"2003","unstructured":"Castro M, Elias LL (2003) Insufici\u00eancia adrenal cr\u00f4nica e aguda. Medicina 36:375\u2013379","journal-title":"Medicina"},{"key":"26_CR88","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berlin) 172:145\u2013156","journal-title":"Psychopharmacology (Berlin)"},{"key":"26_CR89","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00213-011-2434-x","volume":"219","author":"RG dos Santos","year":"2012","unstructured":"dos Santos RG, Grasa E, Valle M, Ballester MR, Bouso JC, Nomdedeu JF, Homs R, Barbanoj MJ, Riba J (2012) Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berlin) 219:1039\u20131053","journal-title":"Psychopharmacology (Berlin)"},{"key":"26_CR90","first-page":"37","volume":"23","author":"G Ona","year":"2018","unstructured":"Ona G (2018) Consideraciones sobre el estado actual de la terapia psicod\u00e9lica: Limitaciones, sesgos y propuestas metodol\u00f3gicas [Considerations on the current state of psychedelic therapy: limitations, bias, and methodological proposals]. Cult Droga 23:37\u201347","journal-title":"Cult Droga"},{"key":"26_CR91","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27:40\u201352","journal-title":"J Psychopharmacol"},{"key":"26_CR92","first-page":"340","volume":"44","author":"R Bahr","year":"2019","unstructured":"Bahr R, Lopez A, Rey JA (2019) Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 44:340\u2013375","journal-title":"P T"},{"key":"26_CR93","first-page":"9","volume":"46","author":"RE Schultes","year":"1986","unstructured":"Schultes RE (1986) El desarrollo hist\u00f3rico de la identificaci\u00f3n de las malpigi\u00e1ceas empleadas Como alucin\u00f3genos [The historical development of the identification of malpighiaceous used as hallucinogens]. Am Indig 46:9\u201347","journal-title":"Am Indig"},{"key":"26_CR94","first-page":"23","volume-title":"The Ethnopharmacology of Ayahuasca","author":"SL Goulart","year":"2011","unstructured":"Goulart SL (2011) The notion of cure in the Brazilian ayahuasca religions. In: dos Santos RG (ed) The Ethnopharmacology of Ayahuasca. Transworld Research Network, Kerala, pp 23\u201353"}],"container-title":["Advances in Experimental Medicine and Biology","Major Depressive Disorder"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-33-6044-0_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T21:20:10Z","timestamp":1617916810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-33-6044-0_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789813360433","9789813360440"],"references-count":94,"URL":"https:\/\/doi.org\/10.1007\/978-981-33-6044-0_26","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"9 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}